Showing results (991-1000 of 1,163) with videos related to

Sort By:
Pageof 117
Nature Medicine|September 1, 2024
Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomesMuthiah Vaduganathan, Gerasimos Filippatos, Brian L Claggett, et al.
JACC. Heart Failure|March 6, 2025
Severe Heart Failure and Treatment With Dapagliflozin Across the Ejection Fraction Spectrum: DAPA-HF and DELIVERRiccardo M Inciardi, Henri Lu, Brian L Claggett, et al.
JAMA Cardiology|February 26, 2025
Finerenone and Outpatient Worsening Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical TrialJonathan W Cunningham, Safia Chatur, Brian L Claggett, et al.
European Journal of Heart Failure|November 13, 2019
Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatmentJan F Nauta, Yoran M Hummel, Jasper Tromp, et al.
European Heart Journal|May 23, 2023
Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trialSafia Chatur, Muthiah Vaduganathan, Brian Claggett, et al.
European Journal of Heart Failure|May 22, 2023
Renal and blood pressure effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: Insights from the DELIVER trialSafia Chatur, Jonathan W Cunningham, Muthiah Vaduganathan, et al.
JACC. Heart Failure|December 6, 2025
Finerenone and Cardiovascular Outcomes According to Baseline Kidney Function in Patients With Heart Failure: The FINEARTS-HF TrialFinnian R Mc Causland, Safia Chatur, Muthiah Vaduganathan, et al.
European Journal of Heart Failure|May 16, 2025
Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trialMisato Chimura, Mingming Yang, Alasdair D Henderson, et al.
European Journal of Heart Failure|October 16, 2025
Artificial intelligence-based echocardiographic assessment for monitoring disease progression in transthyretin cardiac amyloidosisLucia Venneri, Alberto Aimo, Aldostefano Porcari, et al.
JACC. Heart Failure|June 2, 2026
Ambulatory Stage C2D Heart Failure Definitions and Current Therapeutic Approaches: JACC: Heart Failure Position StatementShannon M Dunlay, Monica Colvin, Jennifer A Cowger, et al.
Pageof 117